MITIGATE stands for Closed-loop Molecular Environment for Minimally Invasive Treatment of Patients with Metastatic Gastrointestinal Stromal Tumours.

Gastrointestinal stromal tumour (GIST) is a rare disease and frequently affects young patients and often results in a short life expectancy of less than 3 years. Currently there is only one class of effective medications, for systemic GIST therapy and often the tumours develop drug resistance after a few years. The MITIGATE consortium representing three European universities, three research organisations and four SMEs will pursue the ultimate goal to develop new protocols and guidelines to effectively diagnose and treat patients with metastatic GIST resistant to current treatment.

MITIGATE will host a session at ECR 2016:

Friday, March 4, 14:00-15:30, Room L8
EIBIR 2: MITIGATE: What does it take to perform clinical trials in interventional radiology?

View the session flyer here.

Chairpersons: Stefan O. Schönberg; Mannheim/DE, Werner Jaschke; Innsbruck/AT

Introduction (10′)
Stefan O. Schönberg; Mannheim/DE, Werner R. Jaschke; Innsbruck/AT

Overview on clinical trials in interventional radiology in Europe (20′)
Afshin Gangi; Strasbourg/FR

How to implement investigator initiated or industry sponsored trials in interventional oncology:SORAMIC versus SIRFLOX (20′)
Wolf Richter; Berlin/DE

Design of a clinial trial in oligometastatic GIST:
results from the MITIGATE consortium
Clemens Decristoforo; Innsbruck/AT

Discussion (20′)

For more information on MITIGATE, join the session and stop by the EIBIR booth at ECR 2016 near the main entrance, or visit the project’s website at

MITIGATE is co-funded by the European Community`s Seventh Framework Programme (FP7/2007-20013) under grant agreement no 602306 and will run from October 2013 – 2017.